In contrast to HMGCR inhibitors, LPL targets were associated with reduced risks of cardiovascular events, T2D, hypertension, and NAFLD, indicating the promising roles of developing newer nonstatin therapies through the LPL pathway. The gene discussed is LPL; the disease is metabolic dysfunction-associated steatotic liver disease.